


BSc3094

Cat. No.:	HY-141660
CAS No.:	946857-84-7
Molecular Formula:	C ₁₇ H ₁₂ N ₆ O ₃ S
Molecular Weight:	380.38
Target:	Tau Protein
Pathway:	Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (87.62 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	2.6289 mL	13.1447 mL	26.2895 mL
			5 mM	0.5258 mL	2.6289 mL	5.2579 mL
10 mM	0.2629 mL	1.3145 mL	2.6289 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) ^[1] .
IC ₅₀ & Target	Tau aggregation ^[1]
In Vivo	<p>BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau^[1].</p> <p>BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%^[1].</p> <p>BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the paired-pulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level.</p> <p>BSc3094 partially reversed the memory deficits in rTg4510 mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

Animal Model:	Mice ^[1]
Dosage:	3 mg/kg
Administration:	I.v.
Result:	Direct intraventricular administration reduced sarkosyl-insoluble Tau.
Animal Model:	rTg4510 mice ^[1]
Dosage:	0.075~1.5 mM
Administration:	Intraventricular administration
Result:	Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ~70%.

REFERENCES

[1]. Anglada-Huguet M, et al. Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice. *Alzheimers Dement (N Y)*. 2021;7(1):e12170. Published 2021 Jun 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA